Dana Annunziato

Dana has more than 25 years of experience in the pharmaceutical and CRO industry, with 9 years at Fortrea.

Her clinical research experience spans across global project management and drug development in a broad range of therapeutic areas including neuroscience, in which her expertise lay in several psychiatric indications such as ADHD and schizophrenia, as well as Alzheimer’s disease, and acute and chronic pain indications.

Her experience with Phase I to III studies includes pediatric and adult populations, DEA schedule II and III drugs, in-patient and emergency room/critical care settings, as well as with a variety of drug delivery devices (transdermal, sub-lingual, intranasal, etc.) and diagnostics.